Review Article Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer

Copyright © 2015 Nirmala Chandralega Kampan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Paclitaxel, a class of taxane with microtubule stabilising ability, has remained with platinum based therapy, the standard care for primary ovarian cancermanagement. Adeeper understanding of the immunological basis and other potentialmechanisms of action together with new dosing schedules and/or routes of administrationmay potentiate its clinical benefit. Newer forms of taxanes, with better safety profiles and higher intratumoural cytotoxicity, have yet to demonstrate clinical superiority over the parent compound. 1